Synthetic Biologics Inc (NYSEMKT:SYN) was downgraded by equities researchers at Laurentian Bank of Canada from a “buy” rating to a “speculative buy” rating in a research report issued on Friday, StockTargetPrices.com reports.
SYN has been the subject of a number of other research reports. Griffin Securities set a $5.80 target price on Synthetic Biologics and gave the stock a “buy” rating in a report on Wednesday, August 31st. BTIG Research started coverage on Synthetic Biologics in a report on Thursday, August 25th. They set a “buy” rating and a $5.00 target price for the company. Zacks Investment Research cut Synthetic Biologics from a “buy” rating to a “hold” rating in a report on Wednesday, October 12th. Finally, FBR & Co reiterated a “buy” rating on shares of Synthetic Biologics in a report on Friday, August 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $5.41.
Synthetic Biologics (NYSEMKT:SYN) traded up 1.2302% during trading on Friday, hitting $0.8805. The company had a trading volume of 470,457 shares. The stock has a 50-day moving average of $1.39 and a 200-day moving average of $1.70. Synthetic Biologics has a one year low of $0.82 and a one year high of $3.09. The stock’s market capitalization is $81.16 million.
Synthetic Biologics (NYSEMKT:SYN) last released its earnings results on Tuesday, November 1st. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.01. On average, equities analysts anticipate that Synthetic Biologics will post ($0.35) EPS for the current year.
A hedge fund recently raised its stake in Synthetic Biologics stock. UBS Group AG increased its position in shares of Synthetic Biologics Inc (NYSEMKT:SYN) by 378.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 288,367 shares of the company’s stock after buying an additional 228,037 shares during the period. UBS Group AG owned about 0.32% of Synthetic Biologics worth $680,000 as of its most recent filing with the SEC.
Synthetic Biologics Company Profile